300 related articles for article (PubMed ID: 32204358)
1. Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis.
Bilbao-Ramos P; Serrano DR; Ruiz Saldaña HK; Torrado JJ; Bolás-Fernández F; Dea-Ayuela MA
Molecules; 2020 Mar; 25(6):. PubMed ID: 32204358
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of ursolic acid in experimental visceral leishmaniasis.
Jesus JA; Fragoso TN; Yamamoto ES; Laurenti MD; Silva MS; Ferreira AF; Lago JH; Santos-Gomes G; Passero LF
Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):1-11. PubMed ID: 27984757
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
6. Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis.
de Jesus JA; Laurenti MD; Antonangelo L; Faria CS; Lago JHG; Passero LFD
J Immunol Res; 2021; 2021():6671287. PubMed ID: 33681389
[TBL] [Abstract][Full Text] [Related]
7. Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis.
Ramos GS; Vallejos VMR; Ladeira MS; Reis PG; Souza DM; Machado YA; Ladeira LO; Pinheiro MBV; Melo MN; Fujiwara RT; Frézard F
Biomed Pharmacother; 2021 Feb; 134():111120. PubMed ID: 33341671
[TBL] [Abstract][Full Text] [Related]
8. Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
Pereira IAG; Mendonça DVC; Tavares GSV; Lage DP; Ramos FF; Oliveira-da-Silva JA; Antinarelli LMR; Machado AS; Carvalho LM; Carvalho AMRS; Salustiano IV; Reis TAR; Bandeira RS; Silva AM; Martins VT; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Duarte MC; Menezes-Souza D; Coimbra ES; Leite JPV; Coelho EAF; Gonçalves DU
Parasite Immunol; 2020 Dec; 42(12):e12784. PubMed ID: 32772379
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
10. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
[TBL] [Abstract][Full Text] [Related]
11. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is Related to Programed Cell Death and Presents Therapeutic Potential in Experimental Cutaneous Leishmaniasis.
Yamamoto ES; Campos BL; Jesus JA; Laurenti MD; Ribeiro SP; Kallás EG; Rafael-Fernandes M; Santos-Gomes G; Silva MS; Sessa DP; Lago JH; Levy D; Passero LF
PLoS One; 2015; 10(12):e0144946. PubMed ID: 26674781
[TBL] [Abstract][Full Text] [Related]
13. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
14. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
15. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
[TBL] [Abstract][Full Text] [Related]
16. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
17. Selective effects of Euterpe oleracea (açai) on Leishmania (Leishmania) amazonensis and Leishmania infantum.
Da Silva BJM; Souza-Monteiro JR; Rogez H; Crespo-López ME; Do Nascimento JLM; Silva EO
Biomed Pharmacother; 2018 Jan; 97():1613-1621. PubMed ID: 29793323
[TBL] [Abstract][Full Text] [Related]
18. Effects of nanoemulsions prepared with essential oils of copaiba- and andiroba against Leishmania infantum and Leishmania amazonensis infections.
Dhorm Pimentel de Moraes AR; Tavares GD; Soares Rocha FJ; de Paula E; Giorgio S
Exp Parasitol; 2018 Apr; 187():12-21. PubMed ID: 29518448
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
[TBL] [Abstract][Full Text] [Related]
20. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
